{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT05126472","nct_id":"NCT05126472","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05126472. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Intravesically or intratumorally) of an anti-CD40 agonist antibody (2141-V11) for the treatment of subjects with BCG-unresponsive NMIBC who are considered ineligible for or have elected not to undergo radical cystectomy.","label":"(Cohort A) anti-CD40 antibody 2141-V11","type":"EXPERIMENTAL"},{"description":"Intratumoral 2141-V11 will be administered at the fixed dose of 10 mg established in Cohort\n\nB Part 1. Patients enrolled in Cohort B Part 2 will be randomized 1:1 to one of two treatment arms:\n\nArm 1 (intravesical gemcitabine 2000 mg in 100 mL plus intratumoral 2141-V11 10 mg) or Arm 2 (intravesical gemcitabine 2000 mg in 100 mL monotherapy).","label":"(Cohort B) Part 1 2141-V11, a fixed dose of 10mg , Part 2 Gemcitabine","type":"EXPERIMENTAL"},{"description":"For patients in Cohort C, 10 mg of 2141-V11 will be administered as an intratumoral injection during standard of care cystoscopy no sooner than day 22 of the last cycle of neoadjuvant enfortumab vedotin + pembrolizumab and prior to and within four weeks of planned radical cystectomy.","label":"(Cohort C) expansion cohort 10 mg of 2141-V11","type":"EXPERIMENTAL"}],"collaborators":["Pin Down Bladder Cancer Research Foundation","Rockefeller University"],"completion_date":{"date":"2027-11","type":"ESTIMATED"},"conditions":["Non-muscle Invasive Bladder Cancer"],"enrollment":{"count":115,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"anti-CD40 antibody 2141-V11","otherNames":[],"type":"DRUG"},{"name":"anti-CD40 antibody 2141-V11","otherNames":[],"type":"DRUG"},{"name":"anti-CD40 antibody 2141-V11","otherNames":[],"type":"DRUG"},{"name":"Intravesical Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Intravesical Gemcitabine with anti-CD40 antibody 2141-V11","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-16","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"Phase I/II Study Evaluating the Safety and Tolerability of Locally Administered Anti-CD40 Agonist Antibody (2141-V11) in Subjects With Bladder Cancer","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"MTD/RP2D (Cohort A)","timeFrame":"2 years"},{"measure":"Reported number of adverse events from baseline (start of 2141-V11 administration) up until the last follow-up visit after 2141-V11 administration (Cohort B)","timeFrame":"1 year"},{"measure":"recurrence-free survival (RFS) Cohort B Part 2","timeFrame":"2 years"},{"measure":"Progression of disease","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2021-11-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment","url":"https://clinicaltrials.gov/study/NCT05126472"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05126472"}